Roris Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 M
- Revenue Growth 26.94%
- Profit Growth 103.96%
- Ebitda 25.82%
- Net Worth 88.86%
- Total Assets 37.84%
About Roris Pharmaceuticals
Roris Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 January 2019 (Six years and one month 8 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Upendra Sharma and Kamal Saini serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909RJ2019PTC063618
- Company No.
063618
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Roris Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Upendra Sharma  | Director | 14-Jan-2019 | Current |
| Kamal Saini | Director | 14-Jan-2019 | Current |
Financial Performance of Roris Pharmaceuticals.
Roris Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 26.94% increase. The company also saw a substantial improvement in profitability, with a 103.96% increase in profit. The company's net worth Soared by an impressive increase of 88.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Roris Pharmaceuticals?
In 2023, Roris Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uks Health Care Private LimitedUpendra Sharma and Kamal Saini are mutual person
Charges (Loans)
₹4.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Aug 2022 | Hdfc Bank Limited | ₹4.00 M | Open |
How Many Employees Work at Roris Pharmaceuticals?
Unlock and access historical data on people associated with Roris Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Roris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Roris Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.